Oncology Research and Treatment
Piras A. · Sanfratello A. · Boldrini L. · D'Aviero A. · Pernice G. · Sortino G. · Valerio M.R. · Gennari R. · D'Angelo I. · Marazzi F. · Angileri T. · Daidone A.Log in to MyKarger to check if you already have access to this content.
Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price. Access via DeepDyve Unlimited fulltext viewing Of this article Organize, annotate And mark up articles Printing And downloading restrictions apply Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more Select* The final prices may differ from the prices shown due to specifics of VAT rules.
Article / Publication Details AbstractIntroduction Breast cancer (BC) is one of the most common tumours, better screening policies and multidisciplinary approach allow personalised treatment. Radiotherapy (RT) plays a central role in the multimodal approach in BC, and recent evidence have shown the non-inferiority of hypofractionated treatments. The aim of this study is to describe the feasibility and validity of stereotactic RT (SBRT) in BC in neoadjuvant and exclusive setting. Methods A Pubmed/MEDLINE and Embase systematic review was conducted to assess the role of radiomics in BC. The search strategy was “breast [All Fields] AND "stereotactic" [All Fields] AND "radiotherapy" [All Fields])” and only original articles referred to BC in humans in the English language were considered. Results A total of 2149 studies were obtained using the mentioned search strategy on Pubmed and Embase. After the complete selection process, a total of 12 papers were considered eligible for the analysis of the results. SBRT in BC was described in 8 studies regarding neoadjuvant approach and 4 papers regarding exclusive approach. Conclusions Relative low toxicity rates; the reduced treatment volumes in the neoadjuvant setting and the possibility to replace surgery when not feasible in exclusive setting, resulted to be main advantages for SBRT in BC. Current evidence showed as both the neoadjuvant and the definitive settings seem to be promising clinical scenarios for SBRT especially for EBC.
S. Karger AG, Basel
Article / Publication Details Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
留言 (0)